Carisma Therapeutics

CARM · NASDAQ

$0.0005+$0.0003 (+150.00%)TodayMarket closed · Oct 20, 1:36 PM ET

Prev close $0.0002

CARM analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Jan 26, 2026

Bull case

CARISMA Therapeutics Inc. has effectively preserved optionality for further in vivo CAR-M initiatives, signaling potential growth opportunities should strategic partnerships materialize. The company's recent restructuring efforts, including a significant workforce reduction, are strategically aimed at lowering operational cash burn, thus enhancing financial sustainability. Additionally, the focus on advancing its liver fibrosis and oncology assets positions CARISMA favorably within the competitive landscape of cell therapy development.

Bear case

Carisma Therapeutics has recently adjusted its financial outlook by withdrawing 2025 estimates, resulting in a lowered valuation that indicates significant challenges ahead. The company's revised strategy involves halting several internal research programs, including key therapies for liver fibrosis and solid tumors, which may hinder future growth potential. These strategic shifts underscore a lack of confidence in the pipeline and raise concerns about the company's ability to advance its product offerings in a competitive landscape.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.